Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma Academic Article uri icon

Overview

MeSH Major

  • Boronic Acids
  • Multiple Myeloma
  • Pyrazines
  • Thalidomide

abstract

  • KRd improves GHS/QoL without negatively affecting patient-reported symptoms when compared with Rd. These data further support the benefit of KRd in patients with relapsed multiple myeloma.

publication date

  • November 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.66.9648

PubMed ID

  • 27601539

Additional Document Info

start page

  • 3921

end page

  • 3930

volume

  • 34

number

  • 32